Lumos Pharma announced that interim data from its OraGrowtH210 Trial will be reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society, PES, held in San Diego, California, May 5-8, 2023. Data from the interim analysis of its OraGrowtH212 Trial are also being presented as a poster during the medical meeting.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LUMO:
- Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
- Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
- Lumos Pharma announces additional data from OraGrowtH212 trial
- Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
- Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
